Kairos Pharma shares are trading lower after the company reported statistically significant progression-free survival data from its ongoing Phase 2 clinical trial evaluating ENV-105 to treat prostate cancer. Trial modifications to enroll patients earlier puts Phase 2 completion in or before Q4 2027.